2026-04-23
Kneron Appoints Gene Lay, Founder of BioLegend, to Board of Directors
SAN DIEGO, CA / April 2026 — Kneron, a semiconductor company specializing in energy-efficient edge AI and advanced neural processing systems, today announced the appointment of Gene Lay to its Board of Directors.
Lay is a globally recognized biotechnology entrepreneur with more than four decades of experience spanning scientific research, company formation, and industry leadership. He is the founder of PharMingen and BioLegend, two life science companies that played a foundational role in advancing immunology research worldwide. BioLegend was acquired by Revvity (formerly PerkinElmer) for approximately $5 billion, reflecting the scale and long-term impact of the business he built.
“Gene brings exceptional experience as a founder, operator, and board leader,” said Albert Liu, Founder and CEO of Kneron. “He has successfully built and scaled companies that became essential platforms in their industries. His perspective will be valuable as Kneron expands its edge AI technology into healthcare, life sciences, and scientific computing applications.”
Lay currently serves as Senior Vice President of the Life Sciences Division at Revvity, where he oversees innovation across diagnostics, cellular analysis, immunology, and translational research.He also serves on the Board of Directors of The Scripps Research Institute (TSRI) and is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).
“Kneron is addressing an important need for energy-efficient, secure, on-device AI,” said Lay. “Its technology has meaningful potential in healthcare, diagnostics, and research environments where performance, privacy, and reliability are critical. I look forward to working with the Board and management team to support the company’s long-term strategy.”
Lay is a globally recognized biotechnology entrepreneur with more than four decades of experience spanning scientific research, company formation, and industry leadership. He is the founder of PharMingen and BioLegend, two life science companies that played a foundational role in advancing immunology research worldwide. BioLegend was acquired by Revvity (formerly PerkinElmer) for approximately $5 billion, reflecting the scale and long-term impact of the business he built.
“Gene brings exceptional experience as a founder, operator, and board leader,” said Albert Liu, Founder and CEO of Kneron. “He has successfully built and scaled companies that became essential platforms in their industries. His perspective will be valuable as Kneron expands its edge AI technology into healthcare, life sciences, and scientific computing applications.”
Lay currently serves as Senior Vice President of the Life Sciences Division at Revvity, where he oversees innovation across diagnostics, cellular analysis, immunology, and translational research.He also serves on the Board of Directors of The Scripps Research Institute (TSRI) and is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).
“Kneron is addressing an important need for energy-efficient, secure, on-device AI,” said Lay. “Its technology has meaningful potential in healthcare, diagnostics, and research environments where performance, privacy, and reliability are critical. I look forward to working with the Board and management team to support the company’s long-term strategy.”
